Why I'm not buying CBA shares but would sell everything to buy one ASX stock

I think this stock could outperform the big four bank.

There's a lot to like about Commonwealth Bank of Australia (ASX: CBA). It is an incredible business with a dominant market position and a history of delivering strong shareholder returns.

But I think CBA shares are simply too expensive at current levels.

And if I had to choose just one ASX stock to put my money into instead, there's another company I'd much rather own.

Happy businessman fist pumping while looking at a tablet.

Image source: Getty Images

Why I'm avoiding CBA shares

My biggest issue with CBA is its valuation. The banking giant is currently trading on a forward PE ratio of approximately 25x. That's a huge premium for a mature bank with a relatively subdued earnings growth outlook.

Its recent trading update didn't convince me that this valuation is justified.

CBA reported quarterly cash earnings of approximately $2.8 billion, broadly flat on the second-half FY 2026 quarterly average.

With competition for mortgages and deposits remaining strong, alongside higher operating costs and credit losses, I struggle to see where the earnings growth needed to justify its premium will come from.

If CBA shares were 30% to 40% cheaper, I'd be loading up the truck. But at current levels, I'm happy to look elsewhere.

Why I'd buy this ASX stock instead

One ASX share I'd much rather put all my money into is sleep disorder treatment company ResMed Inc. (ASX: RMD).

I'm a big fan of this business and believe it has an excellent opportunity to continue growing its earnings at a strong rate for many years.

ResMed is a global leader in sleep apnoea treatment, supplying devices and masks to patients around the world.

And with estimates suggesting that approximately one billion people worldwide suffer from sleep apnoea, many of whom remain undiagnosed or untreated, there's a huge opportunity to grow its customer base.

This is being supported by increasing awareness of the condition, improved diagnosis rates, and growing recognition of the health consequences of untreated sleep apnoea.

Importantly, each new patient also creates opportunities for recurring revenue as masks and accessories are replaced.

This is already a major contributor to ResMed's growth. In the first quarter of FY 2027, mask and accessories revenue increased 10% in the Americas and 11% internationally.

More positives

Another thing I like is the company's ongoing investment in innovation and its ability to maintain its leading market position.

It invests heavily in R&D to ensure that its technology remains industry-leading.

And while there have been concerns about the impact of GLP-1 weight-loss medications, ResMed's latest patient research suggests these treatments could actually encourage more people to start and continue sleep apnoea therapy.

Pleasingly, revenue growth is translating into even stronger earnings growth.

In its latest quarter, core revenue increased 7%, while adjusted earnings per share jumped 14%. Management also expects further improvements in profitability through its manufacturing and productivity initiatives.

With a huge market opportunity, growing recurring revenue, and opportunities to improve margins, I believe ResMed could deliver excellent returns over the next decade.

And with a PE ratio of 21x, based on current earnings per share, that's the kind of business I'd much rather own than pay a premium for CBA's slower growth.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Mid-aged couple looking at a laptop.
Blue Chip Shares

I'd buy CBA and BHP shares. But I'd buy this ASX blue chip first

Two of Australia's biggest companies would be on my buy list, but there's another share I'd put ahead of both.

Read more »

Woman using her laptop with her feet up.
Blue Chip Shares

Which ASX 200 share would I buy with $10,000 today?

I think investors could be overlooking some of the ways this business can keep growing its earnings.

Read more »

Couple on their laptop in their home kitchen.
Blue Chip Shares

I'd rather buy these 3 ASX shares than Commonwealth Bank

I'm a big fan of the banking giant but not its valuation.

Read more »

A man and woman watch their device screens, making investing decisions at home.
Blue Chip Shares

If I could choose only one, would I buy Telstra or Wesfarmers shares?

I like both businesses, but if I could only add one to my portfolio today, there's a clear reason behind…

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Blue Chip Shares

Why I'd buy Wesfarmers and Coles shares today

These businesses aren't trading at bargain prices, but I think their long-term opportunities justify a closer look.

Read more »

Happy young couple riding a motorbike together.
Blue Chip Shares

Why I'd buy these ASX blue-chip shares until at least 2036

I'm looking at three established businesses that could become more profitable over the next 10 years.

Read more »

Blue chips with stock written on them.
Blue Chip Shares

2 ASX blue-chip shares offering large dividend yields

I think these businesses have a very compelling future.

Read more »

Three smiling corporate people examine a model of a new building complex.
Blue Chip Shares

3 popular ASX shares I'd happily buy and hold until 2036

Wondering where to invest for the long term? I have my eyes on these shares.

Read more »